Regulatory newsfeed

The latest regulatory updates, in one place

Curated developments across the seven frameworks GORA AI covers — so your launch strategy never runs on stale guidance.

EU MDR12 Jun 2026

EU MDR transitional timelines: what high-risk device makers should confirm now

With staggered transition provisions for legacy devices, manufacturers of Class III and implantable devices should re-confirm Notified Body capacity and conformity-assessment scheduling well ahead of certificate expiry.

Read summary →
Class IIINotified BodyTransition
FDA / CDRH09 Jun 2026

FDA refines 510(k) predicate expectations for cardiovascular catheters

Updated guidance emphasises clearer predicate rationale and performance testing for PTCA and peripheral angioplasty catheters. Teams should align bench, animal, and clinical evidence to the stated product code early.

Read summary →
510(k)PredicateCardiovascular
Swissmedic05 Jun 2026

swissdamed registration: importer and CH-REP obligations in focus

As Switzerland's device database expands, economic operators are reminded to verify CH-REP appointments, CHRN registration, and importer linking to keep market access uninterrupted.

Read summary →
CH-REPswissdamedImporter
EU MDR28 May 2026

EUDAMED modules: planning for mandatory use

As additional EUDAMED modules move toward mandatory status, manufacturers should prepare actor, UDI, and device registration data now to avoid bottlenecks at go-live.

Read summary →
EUDAMEDUDIRegistration
China NMPA22 May 2026

NMPA clarifies clinical evaluation routes for imported devices

Refined expectations on clinical-evaluation exemptions and local data requirements affect registration strategy for overseas manufacturers entering the Chinese market.

Read summary →
RegistrationClinical dataImports
Japan PMDA18 May 2026

PMDA consultation pathways for novel cardiovascular implants

Early consultation continues to shorten review for high-risk implants. Sponsors should scope Shonin requirements and foreign clinical-data acceptability before filing.

Read summary →
ShoninConsultationImplants
FDA / CDRH11 May 2026

Drug-eluting devices: combination-product evidence expectations

For drug-coated balloons and drug-eluting stents, regulators continue to stress integrated safety and effectiveness data reflecting the ancillary medicinal action.

Read summary →
PMACombinationDrug-eluting
Global06 May 2026

Harmonising evidence across markets with a single dossier core

Teams launching in parallel are building a shared evidence core — clinical evaluation, risk management, biocompatibility — then layering jurisdiction-specific requirements on top.

Read summary →
StrategyEvidence coreMulti-market
Australia TGA29 Apr 2026

TGA ARTG inclusion: leveraging comparable overseas approvals

Comparable-overseas-regulator pathways can streamline ARTG inclusion. Confirm conformity-assessment evidence and sponsor responsibilities to use them effectively.

Read summary →
ARTGComparableSponsor
No updates in this category yet — check back soon.

These entries are curated, illustrative summaries for orientation only. Always confirm the current text and effective dates with the relevant authority before acting. Inside the workspace, GORA AI links each requirement to its versioned source record.

Stay current

Get regulatory updates in your workspace

Sign up to track changes by market with versioned sources and update alerts tied to your devices.